Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Observes patient satisfaction and safety of atezolizumab in routine care

Studies how people with lung cancer or liver cancer experience atezolizumab given under the skin.

Key facts

Who runs it
Hoffmann-La Roche
Where
Acquaviva Delle Fonti, Bergamo, Fano (PU), Genoa, Lecce, Mestre, Milan, Misterbianco (CT), Modena, Naples, Novara, Palermo, Ravenna, Rome, Sassari, Trento, and Verona, ItalySee the 22 sitesAlso in 7 other countries, 69 sites
Trial code
Registry title
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Status
Recruiting
People taking part
700 people, planned
Started
15 Jul 2025
Expected to end
31 Dec 2028
Type of study
Observational, 4 groups
Treatments tested
  • Atezolizumab
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with certain lung cancers or liver cancer who are treated with atezolizumab as an injection under the skin in routine care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Early stage non-small cell lung cancer after complete surgery and platinum-based chemotherapy with a high risk of recurrence; metastatic non-small cell lung cancer; extensive-stage small cell lung cancer; or advanced or unresectable liver cancer (hepatocellular carcinoma).
Earlier treatment
Lung cancer and liver cancer cases must not have been treated before in the way the record describes (metastatic non-small cell lung cancer, extensive-stage small cell lung cancer: not previously treated; liver cancer: no earlier systemic therapy). No more than 4 earlier cycles of IV atezolizumab.
Biomarker or test result
Early stage lung cancer: PD-L1 on 50% or more of tumor cells. Metastatic lung cancer: PD-L1 on 50% or more of tumor cells or 10% or more of tumor-infiltrating immune cells. No EGFR mutation or ALK-positive lung cancer.

Main reasons for not taking part

  • Not treated with atezolizumab as standard of care, in line with the approved label
  • Taking other cancer medicine throughout the body at the same time as starting atezolizumab, for the same disease
  • Receiving atezolizumab in a clinical trial or an early or compassionate access program
  • Unwilling to fill in the questionnaires on satisfaction and quality of life

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:; Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC; Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated; Extensive-stage small cell lung cancer (ES-SCLC) not previously treated; Advanced or unresectable HCC not previously treated with systemic therapy
  • Should not have received > 4 prior cycles of IV Atezolizumab

Who cannot take part

  • Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling
  • Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label
  • Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program
  • Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you 18 years old or older?
  • Which best describes your lung cancer?

Where in Italy

Also in 7 other countries, 69 sites

  • Ente Ecclesiastico Ospedale Generale Regionale F MiulliAcquaviva Delle Fonti, ItalyTaking people
  • Cliniche Gavazzeni SpA Humanitas GavazzeniBergamo, ItalyTaking people
  • Azienda Sanitaria Territoriale Pesaro Urbino (AST PU) - Ospedale Santa Croce;UOC Oncologia - Stabilimento di FanoFano (PU), ItalyTaking people
  • IRCCS AOU San Martino - ISTGenoa, ItalyTaking people
  • Presidio Ospedaliero Vito FazziLecce, ItalyTaking people
  • Ospedale dell'AngeloMestre, ItalyTaking people
  • Asst Santi Paolo E CarloMilan, ItalyTaking people
  • Fondazione IRCCS Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
  • Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
  • Humanitas Istituto Clinico Catanese S.p.AMisterbianco (CT), ItalyTaking people
  • A.O. Universitaria Policlinico Di ModenaModena, ItalyTaking people
  • AORN Ospedali dei Colli Ospedale MonaldiNaples, ItalyTaking people
  • Az. Osp. CardarelliNaples, ItalyTaking people
  • A.O.U. Maggiore della CaritàNovara, ItalyTaking people
  • A.O.U. Policlinico Paolo GiacconePalermo, ItalyTaking people
  • Casa di Cura La MaddalenaPalermo, ItalyTaking people
  • Ospedale Provinciale Santa Maria Delle CrociRavenna, ItalyTaking people
  • Policlinico Universitario Agostino GemelliRome, ItalyTaking people
  • Università Campus Bio-Medico di RomaRome, ItalyTaking people
  • Azienda Ospedaliero-Universitaria di SassariSassari, ItalyTaking people
  • Ospedale Santa ChiaraTrento, ItalyTaking people
  • Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyTaking people

About the trial

What the trial wants to find out

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

The 4 groups in the trial

  • Cohort 1: Early Non-small Cell Lung Cancer (NSCLC)

    Participants diagnosed with early-stage NSCLC following complete resection and platinum-based chemotherapy with Programmed Cell-Death Ligand 1 (PD-L1) expression of \>= 50% on Tumor Cell (TC).

    Treatment: Atezolizumab

  • Cohort 2: Metastatic NSCLC

    Participants diagnosed with metastatic NSCLC with PD-L1 expression of \>= 50% on TC who have not received prior systemic therapy for metastatic disease.

    Treatment: Atezolizumab

  • Cohort 3: Extensive stage small cell lung cancer (ES-SCLC)

    Participants diagnosed with ES-SCLC who have not previously been treated.

    Treatment: Atezolizumab

  • Cohort 4: Hepatocellular Carcinoma (HCC)

    Participants diagnosed with advanced or unresectable HCC who have not received prior systemic therapy.

    Treatment: Atezolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice
Plain-language title
Observes patient satisfaction and safety of atezolizumab in routine careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07284121, who can take part
Record updated
6 November 2026